Prentiss Smith & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Prentiss Smith & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3,445	Closed	-$274K	–	309
2016 Q1	$274K	Buy	3,445 +2,945	+589%	+$266K	0.16%	63
2015 Q4	$63K	Hold	500	–	–	0.03%	112
2015 Q3	$52K	Hold	500	–	–	0.03%	116
2015 Q2	$62K	Hold	500	–	–	0.03%	113
2015 Q1	$59K	Hold	500	–	–	0.03%	125
2014 Q4	$59K	Buy	+500	New	+$56.3K	0.03%	132

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Prentiss Smith & Co's VRTX Position: Q2 2016 in Review

Prentiss Smith & Co sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 3,445 shares — an estimated $274K sold.

Prentiss Smith & Co first reported a position in VRTX in Q4 2014 and held it in 6 quarters. The position peaked at $274K in Q1 2016. 483 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

Prentiss Smith & Co reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Prentiss Smith & Co sold 3,445 Vertex Pharmaceuticals shares in Q2 2016, an estimated $274K.
Prentiss Smith & Co first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Prentiss Smith & Co's Vertex Pharmaceuticals position peaked at $274K in Q1 2016.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Prentiss Smith & Co's 13F filing for Q2 2016, filed 28 Jul 2016.